incorporated in 2018, cytomed therapeutics is a spin-off from singapore’s agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into “off-the-shelf” cellular therapeutics using our proprietary technologies for our customers.